Showing posts with label axxe penny stock. Show all posts
Showing posts with label axxe penny stock. Show all posts

Thursday, December 16, 2010

Axxess Pharma, Inc. Enters $35 Billion Arthritis Market (AXXE)

Axxess Pharma, Inc. Enters $35 Billion Arthritis Market Acquiring Canadian Distribution Rights of Unique Pain Relief Medication FORTEX Rubbing Oil(R)

FORTEX Is Sold in 20 Countries Worldwide and Will Now Enter the Canadian Market Where Over 4 Million Canadian Citizens Are Experiencing Arthritis and Soft Tissue Injuries

MARKHAM, ON, Dec 15, 2010 (MARKETWIRE via COMTEX) -- Axxess Pharma Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce the acquisition of FORTEX Rubbing Oil(R) from Actium Pharmaceuticals, Inc. The acquisition now provides Axxess Pharma quick entry into the $35 billion arthritis market. FORTEX is currently sold in 20 countries worldwide. Under the terms of the acquisition, Axxess Pharma now has exclusive distribution rights throughout Canada.

FORTEX is a topical medication requested by physicians on a daily basis. The medication provides rapid and lasting relief of pain associated with musculoskeletal conditions, such as arthritis and soft tissue injuries. Once applied to the skin, FORTEX is readily absorbed directly down to the site of pain. Topical medications such as FORTEX are rapidly expanding due to patients no longer choosing to experience painful side effects caused by their oral pain medication. These side effects are well documented by medical professionals and patients and range from mild, severe and sometimes fatal reactions.

Locally acting topical medications such as FORTEX have the potential to exhibit a safer side effect profile as they deliver the drug directly to the pain site through the skin, resulting in lower levels of the active ingredient entering the blood stream compared to oral medications. Axxess Pharma anticipates strong sales due to demand in the Canadian market.

According to the Arthritis Society of Canada, over 4 million Canadians are diagnosed with arthritis resulting in over 8.8 million physician visits per year for arthritis and related conditions. These numbers are anticipated to continue to increase due to the aging population and obesity.

"I am pleased with Axxess Pharma's business relationship, and the prospects it brings for FORTEX in the Canadian market. FORTEX possesses a unique position for this market. The product works and allows clinicians and patients a cost-effective way to manage musculoskeletal pain and discomfort. This is accomplished by enabling the replacing, decreasing, or adding to, oral-NSAID therapy, which is costly and comes with risks," said Michel Lockhart, representative for Actium Pharmaceuticals.

For more information, please contact Investor Relations at (973) 351-3868.

About Axxess Pharma, Inc.:

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Friday, August 27, 2010

StockProfiler.US: Hot Pharmaceutical Penny Stocks: AXXE & SOHM


MARKHAM, ON, Aug 26, 2010 -- Axxess Pharma Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they anticipate generating an additional $700,000 in annual sales from their pre-natal, non-constipating multi-vitamin Triferrex PN.

Axxess Pharma Inc. closed at $0.024 Thursday, trading 65,800 shares.

Axxess Pharma Inc. Anticipates Additional $700,000 in Annual Sales From Pre-Natal, Non-Constipating Multi-Vitamin Triferrex PN

About Axxess Pharma Inc.

Axxess Pharma Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE penny stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

BUENA PARK, CA, August 27, 2010 -- SOHM, Inc. (PINKSHEETS: SHMN) announced today that it has further broadened its international sales channels in Southeast Asia by signing an exclusive distribution agreement for the marketing and distribution of SOHM's private label generic pharmaceutical products in Sri Lanka.

SOHM, Inc. closed at $0.0610 Thursday, trading 1,895,920 shares.

SOHM Signs Exclusive Agreement for Distribution of Generic Pharmaceuticals in Sri Lanka

About SOHM, Inc.

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters are located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. sohm.com


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free penny stock company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded penny stock companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------

Thursday, August 19, 2010

StockProfiler.US: Pharmaceutical Penny Stock News Alerts: Axxess Pharma, Inc. & Nutra Pharma Corporation


MARKHAM, ON, August 18, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription drugs, wishes to advise shareholders and other interested parties that Senior Management has become aware of an unauthorized press release being disseminated to the public by Mina Mar Marketing Group.

Axxess Pharma, Inc. closed at $0.024 Wednesday, trading 332,828 shares.

Axxess Pharma, Inc. Reports Unauthorized and Inaccurate Press Release Distributed by Mina Mar Marketing Group

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE penny stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

CORAL SPRINGS, FL, August 19, 2010 -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has begun the drug registration process in India for its Nyloxin line of pain relievers.

Nutra Pharma Corporation closed at $0.16 Wednesday, trading 246,915 shares.

Nutra Pharma Begins Drug Registration Process in India for Nyloxin -- A Treatment for Moderate to Severe Chronic Pain

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV). Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin and Nyloxin. For additional information about Nutra Pharma, visit: NutraPharma.com


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free penny stock company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded penny stock companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------

Wednesday, August 18, 2010

StockProfiler.US: Wednesday's Penny Stock Updates: Axxess Pharma, Inc. & Hall of Fame Beverages, Inc.


MARKHAM, ON, August 18, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription drugs, wishes to advise shareholders and other interested parties that Senior Management has become aware of an unauthorized press release being disseminated to the public by Mina Mar Marketing Group.

Axxess Pharma, Inc. closed at $0.028 Tuesday, trading 150,000 shares.

Axxess Pharma, Inc. Reports Unauthorized and Inaccurate Press Release Distributed by Mina Mar Marketing Group

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE penny stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

LOS ANGELES, CA, August 18, 2010 -- Hall of Fame Beverages, Inc. (PINKSHEETS: HFBG) CEO Steve Hendricks announces that the company's first production run of its brand Grand Ma Ma's Sweet Southern Tea is complete.

Hall of Fame Beverages, Inc. closed at $0.0005 Tuesday, trading 15,704,000 shares.

Hall of Fame Beverages CEO Announces the Return of Grand Ma Ma

About Hall of Fame Beverages

Hall of Fame Beverages, Inc. is a new lifestyle company dedicated to building long-term success through the creation, manufacture, distribution, and marketing of innovative non-alcoholic beverages recognized for their fresh, standout brand identities that rise above the plethora of average products. Hall of Fame Beverages is a team of visionary and seasoned beverage industry executives who intend to leverage their expertise and their established resources in beverage commerce to make Hall of Fame Beverages one of the industry's big winners via its signature brands Atomic Dogg Super Soda and Grand Ma Ma's Sweet Southern Tea.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free penny stock company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded penny stock companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------

Thursday, August 12, 2010

StockProfiler.US: Urgent Pharmaceutical Stock News Alerts: Axxess Pharma, Inc. & Novavax, Inc.


ONTARIO, CA, August 12, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription drugs, announces on June 14, 2010 Taylor Capitol, Inc was hired as Investor Relations to replace Mina Mar Marketing Group.

Axxess Pharma, Inc. closed at $0.012 Wednesday, trading 139,700 shares.

Axxess Pharma, Inc. Provides Update Regarding Mina Mar Marketing Group

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE penny stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

ROCKVILLE, Md., Aug. 12, 2010 -- Novavax, Inc. (NASDAQ: NVAX) reported today that results from a pre-clinical toxicology study of its vaccine candidate to prevent respiratory syncytial virus (RSV), showed the vaccine to be safe and well-tolerated at all doses tested.

Novavax, Inc. closed at $2.17 Wednesday, trading 840,300 shares.

Novavax Reports Positive Results from Pre-Clinical Safety Study of Respiratory Syncytial Virus (RSV) Vaccine Candidate

About Novavax, Inc.

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics inIndia. Additional information about Novavax is available on the company's website: novavax.com.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free penny stock company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded penny stock companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------
Keywords: axxe, axxe stock, axxe stock news, axxe stock alerts, axxe company news, axxe penny stock, penny stock news, penny stock alerts, penny stock updates, penny stock news updates, penny stock profile

Tuesday, August 10, 2010

StockProfiler.US: Pharmaceutical Companies in the News: Axxess Pharma, Inc. & Bionovo, Inc.


MARKHAM, ON, August 9, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce Health Canada approved 11 of their prescription and non-prescription drugs.

Axxess Pharma, Inc. closed at $0.0151 Monday, trading 546,935 shares.

Axxess Pharma, Inc. Reports Health Canada Approves 11 Prescription and Non-Prescription Drugs

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE penny stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

EMERYVILLE, Calif., Aug. 10, 2010 -- Bionovo, Inc. (NASDAQ: BNVI), a drug discovery and development company focused on the unmet needs in women's health and oncology, announced that LifeTech Capital has initiated independent research coverage on the Company.

Bionovo, Inc. closed at $0.40 Monday, trading 262,500 shares.

LifeTech Capital Initiates Coverage of Bionovo

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The Company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: bionovo.com.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free penny stock company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded penny stock companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------
Keywords: axxe, axxe stock, axxe stock news, axxe stock alerts, axxe company news, axxe penny stock, penny stock news, penny stock alerts, penny stock updates, penny stock news updates, penny stock profile

Thursday, August 5, 2010

StockProfiler.US: Penny Stock Pharmaceutical Company News: Axxess Pharma, Inc. & Advanced Life Sciences Holdings, Inc.


ONTARIO, CA, August 5, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they have signed an exclusive license agreement to market and distribute a high potency, highly concentrated vitamin D-3 capsule.

Axxess Pharma, Inc. closed at $0.023 Wednesday, trading 130,000 shares.

Axxess Pharma, Inc. Signs Exclusive License Agreement to Globally Market and Distribute High Potency Vitamin D-3 to Help Reduce Bone Loss and Joint Pain

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE penny stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

CHICAGO, Aug. 5, 2010 -- Advanced Life Sciences Holdings, Inc. (OTCBB: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has been featured as a special stock pick for August, 2010 by "The KonLin Letter," a 27 year old independent, financial newsletter.

Advanced Life Sciences Holdings, Inc. closed at $0.057 Wednesday, trading 1,620,535 shares.

Advanced Life Sciences Featured as Special Stock Pick by KonLin Investment Letter

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza™, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including community acquired bacterial pneumonia (CABP) and biodefense pathogens including anthrax, plague and tularemia.  In June 2010, the Company submitted a Special Protocol Assessment (SPA) with the FDA for the proposed Phase III clinical program of Restanza in the treatment of patients with CABP. The Company has been engaged in the SPA process with the FDA over the last year to establish the clinical trial design needed to gain approval in CABP. As filed, the updated SPA incorporates written and oral comments from the FDA's Division of Anti-Infective and Ophthalmology Products.  Based on the FDA's review cycle, the Company expects a reply to its submission by mid-August of this year.

The opinions expressed in "The KonLin Letter" are those of the analyst and not of Advanced Life Sciences. Advanced Life Sciences does not accept responsibility for the accuracy of any of the information or statements contained in this report. For information provided by Advanced Life Sciences with respect to its business and business prospects, as well as associated risks with an investment in the Company's stock, please see the Company's reports filed with the Securities and Exchange Commission, copies of which are available at www.sec.gov.

For more information, please visit us on the web at advancedlifesciences.com or follow us on twitter at twitter.com/advancedlifesci.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free penny stock company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded penny stock companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------
Keywords: axxe, axxe stock, axxe stock news, axxe stock alerts, axxe company news, axxe penny stock, penny stock news, penny stock alerts, penny stock updates, penny stock news updates, penny stock profile